Janssen
Early-stage research gains another funding boost
March 23, 2012Research and Development, Sales and Marketing GSK, Index Ventures, Janssen, R&D
GlaxoSmithKline and Janssen are among the key investors in a venture capital fund aimed solely at identifying promising pharma start-ups. …
NICE recommends Incivo for hepatitis C
March 16, 2012Sales and Marketing Incivo, Janssen, NICE, Victrelis, telaprevir
NICE is recommending Janssen’s hepatitis C pill Incivo for funding on the NHS in England. The drug has bypassed the …
Charity attacks Scottish decision on Zytiga
March 14, 2012Sales and Marketing Janssen, NICE, PAS, Prostate Cancer Charity, Zytiga
Scotland’s medicines regulator has turned down Janssen’s prostate cancer pill Zytiga, leading to a backlash from charities. The Scottish Medicines …
Strong Zytiga study results could increase uptake
March 12, 2012Research and Development, Sales and Marketing IDMC, Janssen, Provenge, Zytiga, prostate
Janssen’s prostate cancer pill Zytiga could be on course to target a larger number of patients following a positive late-stage …
NICE recommends Victrelis in speedy review
March 9, 2012Sales and Marketing Incivo, Janssen, Merck, NICE, Pegasus, Victrelis
NICE is recommending Merck’s hepatitis C pill Victrelis for funding in the NHS, in an expedited review. In its final …
Cancer Drugs Fund should not be used across the UK
March 7, 2012Sales and Marketing CDF, Janssen, NICE, Zytiga, myloma, prostate
The Prostate Cancer Charity has said that extending England’s Cancer Drugs Fund to the UK will not solve the issue …
Janssen launches hep C support programme
February 27, 2012Medical Communications, Sales and Marketing BUPA, Copegas, Incivo, Janssen, Pegasys, hep C
Janssen has launched a hepatitis C support programme for patients in the UK to help with medicine adherence and healthy …
Alex Gorsky named new chief executive of J&J
February 22, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alex Gorsky, J&J, JJ, Janssen, Weldon
Johnson & Johnson has named Alex Gorsky as its new chief executive, effective from 26 April. Gorsky was also nominated …
Zytiga approved in Wales – for now
February 21, 2012Sales and Marketing AWMSG, CDF, Janssen, NICE, Wales, Zytiga
Janssen’s cancer treatment Zytiga has been approved in Wales, in contrast to its rejection by NICE. The All Wales Medicines …
Janssen signs deal with rising star Forma
January 11, 2012Research and Development Forma, Janssen, alliance
Janssen has signed a deal with Forma Therapeutics to discover, and develop drugs that target tumour metabolism mechanisms.Forma focuses on …
J&J to pay $1 billion for Risperdal charges
January 9, 2012Sales and Marketing J&J, JJ, Janssen, Risperdal
Johnson & Johnson will pay more than $1 billion in the US to resolve a civil investigation into the marketing …
Janssen inks $150m deal for blood cancer drug
December 12, 2011Research and Development, Sales and Marketing Janssen, Pharmacyclics
Janssen biotech has signed a licensing deal with Pharmacyclics for its investigational blood cancer drug. The firm has paid $150 …
Janssen sets up new mental health social networking site
November 28, 2011Medical Communications J&J, JJ, Janssen, NHS
Janssen and the NHS Confederation have established a new mental health social networking site. The service, which will be free …
Alex Butler leaves Janssen to set up Social Moon pharma network
October 27, 2011Medical Communications Alex Bytler, Jansse, Janssen, comms
Social media guru Alex Butler has left Janssen to establish Social Moon, a digital-only marketing and comms agency for the …
European approval for prostate cancer drug Zytiga
September 8, 2011Sales and Marketing Janssen, Jevtana, Johnson & Johnson, Zytiga, prostate cancer
Johnson & Johnson’s Zytiga has been approved in the EU for late-stage prostate cancer. Zytiga (abiraterone acetate) is now licenced …
Latest content
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
